Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Zydus Lifesciences jumps 5% as board to consider buyback, results on May 19
The buying on the counter came after the company, through a filing, said that its board will consider a buyback in a meeting along with the financial results on Tuesday, May 19, 2026
Zydus Lifesciences sets board meeting date to consider buyback of shares. Details here - Mint
Zydus Lifesciences sets board meeting date to consider buyback of shares. Details hereMint
Stocks to watch: HAL, IRFC, Bharti Airtel, Zydus Lifesciences among 10 shares in focus today - Mint
Stocks to watch: HAL, IRFC, Bharti Airtel, Zydus Lifesciences among 10 shares in focus todayMint
Here's why today and May 19 are important sessions for Zydus Life shareholders
Zydus Lifesciences will acquire Assertio Holdings for $23.5 per share in cash, valuing the transaction at $166.4 million. Assertio is a US-based specialty pharmaceutical company with a focus on oncology and pain management.
Stocks in news: HAL, TMPV, Bharti Airtel, Anant Raj, Zydus Life, Tata Motors
Indian markets experienced a volatile yet stable session after a sharp sell-off, with the Nifty showing resilience. Key companies like HAL, Tata Motors, and Bharti Airtel are in focus due to quarterly results and news developments. Zydus Lifesciences is nearing a US acquisition, while Maruti Suzuki commits to green logistics.
Zydus Lifesciences acquires US pharma firm Assertio for $166 million
In a bold move that positions Zydus at the forefront of the U.S. specialty oncology market, the Indian drug manufacturer has secured a $166.40 million deal to acquire Assertio Holdings. The purchase includes Assertio’s essential cancer treatment, Rolvedon, and offers Zydus a rich commercial network to elevate its oncology initiatives.
Zydus Lifesciences close to buying US oncology drug maker for $100 to 150 million: Sources
Indian drug maker Zydus Lifesciences is close to acquiring a US company. The deal is expected to be between $100 to $150 million. This acquisition will help Zydus build its own distribution network for anti-cancer drugs in the US. The target company also has its own pipeline of biologic drugs. A deal is anticipated soon.
Zydus Lifesciences may buy back shares; board meeting scheduled on May 19
Zydus Lifesciences said its board will consider a share buyback proposal on May 19, with the stock trading slightly higher on the NSE.
Zydus Biologics’ Ahmedabad injectable facility gets 7 observations in USFDA inspection
Zydus Lifesciences has made headlines as its Zydus Biologics injectable plant in Ahmedabad underwent a USFDA inspection between April 27 and May 5, 2026. The inspection yielded seven observations, but significantly, there were no issues regarding data integrity. Zydus Lifesciences is already in discussions with the USFDA to ensure these observations are addressed in a timely manner.
Zydus Lifesciences Ltd rises for third straight session
Zydus Lifesciences Ltd is quoting at Rs 934.15, up 2.4% on the day as on 12:49 IST on the NSE. The stock is up 5.42% in last one year as compared to a 1.62% slide in NIFTY and a 12.19% slide in the Nifty Pharma index.
Zydus Lifesciences receives seven observations from USFDA for biologics injectable plant in Ahmedabad
Zydus Life said the US Food and Drug Administration (USFDA) conducted the good manufacturing practices (GMP) surveillance inspection at its Unit 9 facility at Zydus Biotech Park in Changodar, Ahmedabad, from April 27 to May 5, 2026.
Guardant Health to launch blood-based cancer test in India with Zydus Lifesciences
Guardant Health is set to introduce a groundbreaking blood test in India for early cancer detection. This multi-cancer test, developed with Zydus Lifesciences, aims to identify various cancers like lung, breast, and prostate. The initiative targets India's high cancer burden and low screening rates.